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Abstract
Background: The aim of our study was to investigate and evaluate the prognostic value of and
correlations between preclinical and clinical factors such as the stage of the disease, blood Hb level
before treatment, size of cervix and lymph nodes evaluated by CT, age, dose of irradiation and
duration of radiotherapy related to overall survival, disease-free survival, local control and
metastases-free survival in cervical cancer patients receiving radiotherapy alone.
Methods: 162 patients with International Federation of Gynecology and Obstetrics (FIGO) stage
IIA-IIIB cervical carcinoma treated with irradiation were analysed. Univariate and multivariate
analyses using the Cox regression model were performed to determine statistical significance of
some tumor-related factors.
Results: The Hb level before treatment showed significant influence on overall survival (p = 0.001),
desease free survival (p = 0.040) and local control (p = 0.038). The lymph node status (>10 mm)
assessed on CT had impact on overall survival (p = 0,030) and local control (p = 0,036). The dose
at point A had impact on disease free survival (p = 0,028) and local control (p = 0,021) and the
radiotherapy duration had showed significant influence on overall survival (p = 0,045), disease free
survival (p = 0,006) and local control (p = 0,033).
Conclusion: Anemia is a significant and independent prognostic factor of overall survival, disease-
free survival and local control in cervical cancer patients treated with irradiation. The size of lymph
nodes in CT is an independent prognostic factor for overall survival and local control in cervical
cancer patients. The size of cervix uteri evaluated by CT has no prognostic significance in cervical
cancer patients treated with radiotherapy. The prognostic value of FIGO stage of cervical cancer
is influenced by other factors, analyzed in this study and is not an independent prognostic factor.
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Background
In 2004, 569 new cases of cervical cancer were diagnosed
in Lithuania. This number is higher (by about 100 cases)
than that observed in 2003. The lifetime risk of cervical
cancer in Lithuania is 1 of 65 women. Most often cervical
cancer develops in women aged 30 to 59 years, i.e. when
they are most able-bodied. In 33% of patients stage I and
in 21% – stage II were diagnosed. Advanced cervical can-
cer (stages III and IV) was diagnosed in 46% of patients
[1]. Radiotherapy was usually used in stages II-IV cervical
cancer. About 60% of patients with cervical cancer in
Lithuania used to undergo radiotherapy. Now the golden
standard in advanced cervical cancer patients treatment is
chemoradiotherapy, but this treatment option is more
toxic and may be not everyone needs such aggressive treat-
ment. Therefore it is very important to define the factors
that influence results in radiotherapy.
The FIGO (The International Federation of Gynecology
and Obstetrics) classification [2] is used to define the stage
of the cervical cancer. Once established, the stage should
not be changed. Clinical examination of the patient is of
crucial importance in the staging of cervical cancer. Stage
is determined according to tumor extension beyond the
uterine cervix and its invasion into adjacent tissues: para-
metric, pelvic wall, vagina, bladder and rectum. Radiolog-
ical investigations involve only chest X-ray for evaluating
lung metastases and intravenous urograms for determin-
ing the presence of hydronephrosis. No modern methods
of radiological investigations such as CT, MRI, PET are
used for the staging of cervical cancer according to FIGO
classification [3-8].
According to the current FIGO classification, cancer
patients are divided into groups, and 5 – year survival
within these groups is different [9,10]. The incidence lev-
els differ significantly within every stage [11-14]. There-
fore, it could be assumed that the present criteria of
staging are insufficient, and there are some other factors
that influence survival; these factors should be taken into
consideration when selecting treatment options [15-18].
The goal of our study was to determine the factors influ-
encing the survival of advanced cervical cancer patients.
Methods
This was a cohort retrospective study. Case histories of
350 patients treated with radiotherapy due to stage II and
III cervical cancer at the Institute of Oncology, Vilnius
University in 1999–2003 were analyzed. 162 patients
who met inclusion and exclusion criteria were involved
into the study.
Inclusion criteria:
￿ Histologically confirmed cervical cancer
￿ FIGO stage II-III
￿ Only combined radiotherapy (EBRT+Brachytherapy)
￿ Pelvic CT scan before treatment
￿ The treatment was performed using a linear accelerator.
Exclusion criteria:
￿ Follow-up duration <1 year
￿ Treatment started before 1999
￿ Second primary tumor (except skin non-melanomas).
The censoring time was March 2005. The minimal dura-
tion of follow-up was one year (365 days), the maximal
being 5.8 years (2108 days), mediana – 2.7 years (992
days (95% CI 911–1127), 32 months. The patients' age
ranged from 21 to 81 years. The distribution by age groups
was the following: younger than 50 years – 74 patients
(45.7%), from 50 to 64 – 60 (37%), older than 64 years –
28 (17,3%). The median age was 50 years (95% CI,
49.0–54.0), average age being 52 years. The stage was
evaluated by the oncologist-gynecologist according to
FIGO criteria. There were 69 patients with stage II (43.6%)
and 93 patients with stage III (57.4%). According to the
morphology of tumor the patients were distributed into 5
groups: squamous cell carcinoma G1 – 4 (2.2%), squa-
mous cell carcinoma G2 – 37 (20.4%), squamous cell car-
cinoma G3 – 137 (75.1%), adenocarcinoma – 2 (1.1%);
other – 1 (0.5%). Blood count was performed and blood
Hb level evaluated in all patients before treatment.
According to the results of this test the patients were
divided into two groups: Hb <120 g/l and Hb > 120 g/l.
There were 68 patients with a lower level of Hb (<120 g/
l) (42.0%), and 94 patients with Hb>120 g/l (58.0%).
Combined radiotherapy involving external irradiation
and intracavitary radiotherapy was applied to all patients.
They were irradiated with 25 MeV photons using a linear
accelerator and four adapted fields with a blocking system
("box" method). The upper border of the field was at the
level of L4-L5 intervertebral space, the lower border being
at the level of the middle of the obturator foramen. The
lateral borders of frontal fields involve 1 cm of the bone
pelvis. Single focal dose (SFD) of external irradiation was
2 Gy. Patients were irradiated 5 days a week. The doses
were calculated for points A and B. Point A is located 2 cm
aside from the middle line and 2 cm above the lateral
vaults of the vagina. This is the point of cervix uteri that
corresponds to the top of the paracervical triangle. Point B
is located 5 cm aside from the middle line and 2 cm above
the lateral vaults of the vagina. This is the point in the par-BMC Cancer 2007, 7:234 http://www.biomedcentral.com/1471-2407/7/234
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ametrium. For the majority of patients the dose of EBRT
(2 Gy per fraction) was prescribed to the central axis point
of beam intersection. Box technique was employed for
these patients. Dose homogenity throughout the CT out-
lined treatment volume satisfied ICRU 50 requirements.
For some patients, however, the central blocking from AP-
PA fields was used. The prescription point (2 Gy per frac-
tion) in this case was located 1 cm laterally from the phys-
ical edge of the block. The lowest dose of external
irradiation at point A was 23 Gy, the highest dose at this
point being 55 Gy; the median dose was 37 Gy (95% CI,
35.6 – 38.4). The lowest dose of external irradiation at
point B was 28 Gy, the highest dose being 60 Gy; the
median dose was 50 Gy (95% CI 49.1–50.9). For intrac-
avitary irradiation, an AGAT-VU irradiation machine with
a Co60 source (1,25 MeV energy) and the Fletcher type
applicator was used. The average fraction dose was 7 Gy.
One to six fractions (on average 4 fractions) were applied.
The procedure was performed once a week. The lowest
dose of intracavitary irradiation at point A was 8 Gy, and
the highest dose at this point was 48 Gy, the median dose
was 40 Gy (95% CI, 38.1 – 41.9). The lowest dose at point
B was 2 Gy, the highest dose being 20 Gy and the median
dose was 10 Gy (95% CI, 8.8 – 11.2). Total treatment dose
(EBRT+Brachytherapy) for patients described in the study
was 76 Gy (median) for the point A and 60 Gy (median)
for the point B.
In the Institute of Oncology, Vilnius University, non-con-
trast computed tomography of pelvic organs is performed
during pre-treatment planning of cervical cancer patients
undergoing radiotherapy. We used a General Electric Syn-
tec Synergy computed tomography machine without spi-
ral software. CT scans were performed from the upper
edge of the ileum wing down to the ischial tuberosity; the
axial slices were made with slice spaces of 10 mm. The sta-
tus of pelvic organs and the size of pelvic lymph nodes
were assessed. The smallest size of all visible lymph nodes
was measured. The patients were assigned to one of the
three study groups according to the results of these meas-
urements: 73 patients without CT evidence of pelvic
lymph nodes (45.0%), 51 patient with lymph nodes from
1 to 10 mm (31.5%); and 38 patients with lymph nodes
10 mm and larger. The size of cervix, its greatest diameter
was also measured. By this factor the patients were divided
into two study groups: size of cervix < 60 mm, and size of
cervix ≥60 mm. There were 81 patients (50.0%) in the first
and 71 (4.8%) in the second group. In 10 patients cervix
size has been not recorded and there were no respective
data in patients' case histories. The size of cervix but not
the size of tumor was selected, because the resolution of
soft tissues in computed tomography is not sufficient to
evaluate a single tumor precisely. Since this method is
used in our everyday work for pre-treatment planning, our
goal was to clarify how this method alone could be used
for the prognosis of the course of the disease.
We analyzed how such factors as the stage of the disease,
blood Hb level before treatment, size of cervix and lymph
nodes evaluated by CT, age, dose of irradiation and dura-
tion of radiotherapy influence the overall survival, dis-
ease-free survival, local control and distant-metastases-
free survival. Overall survival was calculated evaluating
the time from the end of treatment to the last follow-up or
death. Disease-free survival was evaluated calculating the
time from the end of treatment to any disease progression
(local recurrence or distant metastases). Local control was
evaluated calculating the time from the end of treatment
to any recurrence in the pelvis. Distant-metastases-free
survival was evaluated calculating the time from the end
of treatment to any disease progression outside the pelvis.
Survival analysis was performed using the Kaplan-Meier
method. Differences in the rate and their significance were
evaluated using the log-rank test (p < 0,05). Interrelations
of the analyzed factors were evaluated using cross-tabula-
tion and the Cox proportional hazard model. Probability
of complications after radiotherapy was assessed using the
probit method. Statistical analysis was performed using
the STATA software.
Ethics
The study protocol was reviewed and approved by the
Lithuanian Bioethical Committee and complied with the
recommendations of the Declaration of Helsinki for bio-
medical research involving human subjects.
Results
The Kaplan-Meier method was used to assess the impor-
tance of factors we have selected (age, stage of the disease,
Hb blood level before treatment, size of cervix and lymph
nodes evaluated on CT, irradiation dose and radiotherapy
duration) influencing the overall survival, disease-free
survival, local control and distant-metastases-free survival
of patients with cervical cancer (Table 1).
The overall survival for the whole cohort of our study was
71,7% (95%CI 63.7%–78.3%) and disease-free survival
was 74,2% (95%CI 66.2%–80.7%).
There were no significant effect of patient age on overall
survival (OS): patients < 50 had a 3-year OS of 64%
(95%CI 51.3%–74.3%), 78,8% (95%CI 65.6%–87.4%)
for age 50–64 and 76.3% (95%CI 54.2%–88.8%) for > 64
years (p = 0.2960); and on disease free survival (DFS):
patients < 50 had a 3-year DFS of 70.7% (95%CI
58.1%–80.13%), 76.5% (95%CI 62.8%–85.8%) for age
50–64 and 79.8% (95%CI 57.4%–91.2%) for > 64 years
(p = 0.4513). There were also no significant differences
between the patients groups with different size of the cer-BMC Cancer 2007, 7:234 http://www.biomedcentral.com/1471-2407/7/234
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vix evaluated by CT on OS and on DFS: patients <60 mm
had a 3-year OVS of 75.3% (95%CI 63.9%–83.5%), DFS
of 74.4% (95%CI 62.9%–82.8%) and patients ≥60 mm
had a 3-year OS 66.4% (95%CI 53.2%–76.7%), DFS
69.2% (95%CI 56.9%–78.6%), p = 0.4882. The effect of
lymph nodes (LN) size assessed by CT on OS is shown in
Figure 1. Patients with no evidence of lymph nodes on CT
had a 3-year OS of 76.9% (95%CI 64.2%–85.6%), 79.5%
(95%CI 65.0%–88.5%) with lymph nodes being 1–10
mm and 51.2% (95%CI 34.2%–65.9%) with lymph
nodes being ≥1 0  m m  i n  h i s  s h o r t e s t  a x i s  o n  C T  ( p  =
0.0048). We looked for lymph nodes size assessed by CT
effect on DFS (Figure 2). Patients with no evidence of
lymph nodes on CT had a 3-year DFS of 78.8% (95%CI
66.4%–87.0%), 76.2% (95%CI 60.7%–86.3%) with
lymph nodes being 1–10 mm and 62.0% (95%CI
43.4%–76.0%) with lymph nodes being ≥10 mm (p =
0.0498). Initial hemoglobin levels <120 g/l were associ-
ated with a 55.4% (95%CI 42.2%–66.7%) OS and 71.0%
(95%CI 57.8%–80.8%) DFS compared with 83.5%
(95%CI 73.6%–90.9%) OS and 87.9% (95%CI
78.3%–93.4%) DFS if the hemoglobin was ≥120 g/l (Fig-
ures 3 and 4). OS and DFS as a function of FIGO stage
were 87.9% (95%CI 77.1%–93.8%) and 83.3% (95%CI
71.8%–90.5%) for stage II, 59.1% (95%CI
47.6%–68.9%) and 66.6% (95%CI 54.6%–76.1%) for
stage III (Figures 5 and 6). Radiation doses to point A of
<76 Gy were associated with a 71.2% (95%CI
58.3%–80.8%) OVS and 71.7% (95%CI 57.7%–81.7%)
DFS whereas with doses ≥7 6  G y  t h e  O S  w a s  7 2 . 6 %
(95%CI 61.8%–80.8%) and DFS was 75.9% (95%CI
57.8%–81.7%). Radiation doses to point B of <60 Gy
were associated with 78.7% (95%CI 66.1%–87.0%) OS
and 81.3% (95%CI 68.7%–89.2%) DFS whereas with
doses ≥60 Gy the OS was 68.5% (95%CI 58.0%–76.9%)
and DFS was 70.4% (95%CI 59.6%–78.8%). These differ-
ences were not statistically significant. Treatment dura-
tions of 56 days or less were associated with OS of 84.7%
(95%CI 70.5%–92.4%) and with DFS of 86.9 (95%CI
73.0%–93.9%), 57–70 days were associated with OS of
72.6% (95%CI 60.1%–81.7%) and with DFS of 73.3%
(95%CI 60.0%–82.9%) compared with OS of 53.8%
(95%CI 35.7%–68.8%) and DFS of 58.2% (95%CI
39.7%–72.9%) in patients with duration of more than 71
day (Figures 7 and 8).
Disease free survival according to lymph nodes (LN) size on  CT Figure 2
Disease free survival according to lymph nodes (LN) size on 
CT.
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Table 1: Univariate analysis of prognostic factors by Cox proportional hazard model: overall survival and disease-free survival at 3 
years
Factor Overall survival
RR (95% CI)
p value Disease-free survival
RR (95% CI)
p value
Age 0.98 (95% CI, 0.96–1.01) 0.2735 0.98 (95% CI, 0.96–1.01) 0.231
Stage 3.96 (95% CI, 1.90–8.24 0.0000 2.81 (95% CI, 1.40–5.63) 0.004
L/node size by CT 1.62 (95% CI, 1.14–2.32) 0.0078 1.54 (95% CI, 1.06–2.23) 0.023
Cervix size by CT 1.41 (95% CI, 0.85–2.33) 0.1754 1.03 (95% CI, 0.72–2.01) 0.478
Hb blood level 0.27 (95% CI, 0.15–0.51) 0.000 0.39 (95% CI, 0.21–0.73) 0.003
Dose at point A 0.90 (95% CI, 0.50–1.62) 0.7360 0.98 (95% CI, 0.53–1.81) 0.953
Dose at point B 1.49 (95% CI, 0.78–2.83) 0.2144 1.74 (95% CI, 0.87–3.46) 0.117
Duration of treatment 1.85 (95% CI, 1.24–2.76) 0.0024 2.06 (95% CI, 1.34–3.15) 0.001
Overall survival according to lymph nodes (LN) size on CT Figure 1
Overall survival according to lymph nodes (LN) size on CT.
  p=0.0048 
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We used the Cox proportional hazard model to evaluate
the significance of the factors we have selected (age, stage
of the disease, blood Hb level before treatment, size of cer-
vix and lymph nodes evaluated by CT, irradiation dose
and radiotherapy duration) influencing the overall sur-
vival, disease-free survival, local control and distant-
metastases-free survival of cervical cancer patients (uni-
variate analysis, Table 1 and 2); we have also used this
method to assess how the prognostic significance of these
factors depends on the other factors analyzed (multivari-
ate analysis, Table 3 and 4).
Univariate Cox regression analysis has shown (Table 1
and 2) that the stage of the disease, the lymph nodes size
evaluated on CT, blood Hb level before treatment and
radiotherapy duration are statistically significant prognos-
tic factors for overall survival. Stage, the lymph nodes size
evaluated on CT, blood Hb level before treatment and
radiotherapy duration are statistically significant prognos-
tic factors for disease-free survival. These factors are also
statistically significant prognostic factors for local control
survival. The size of lymph nodes evaluated by CT and the
duration of radiotherapy are statistically significant prog-
nostic factors for distant-metastases-free survival.
The multivariate Cox analysis has shown (Table 3 and 4)
that the size of lymph nodes assessed by CT, blood Hb
level before treatment and radiotherapy duration are
independent prognostic factors for overall survival. Radi-
otherapy duration and blood Hb level are independent
prognostic factors for disease-free survival. Although stage
and the lymph nodes size evaluated by CT are statistically
significant prognostic factors for disease-free survival
when assessed alone, they lose their significance when
analyzed together with other factors. The dose at point A
has no prognostic significance when analyzed alone; how-
Disease-free survival according FIGO stage Figure 6
Disease-free survival according FIGO stage.
  p=0.0024 
 
S
u
r
v
i
v
a
l
 
Years
0  1  2 3 4 5 6  7 
   0% 
  25% 
  50% 
  75% 
100% 
Stage II (n=69) 
Stage III (n=93)  
 
Disease-free survival as a function of initial hemoglobin level Figure 4
Disease-free survival as a function of initial hemoglobin level.
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Overall survival as a function of initial hemoglobin level Figure 3
Overall survival as a function of initial hemoglobin level.
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Overall survival according to FIGO stage Figure 5
Overall survival according to FIGO stage.
  p=0.0001 
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ever, it becomes statistically significant when analyzed
together with other factors. Our data show that the size of
lymph nodes evaluated by CT, blood Hb level before
treatment and radiotherapy duration remain independent
prognostic factors influencing local control. However, the
dose at point A is of no prognostic significance for local
control when analyzed alone, but it acquires a statistically
significant prognostic value when analyzed together with
other factors. None of the factors analyzed is an independ-
ent prognostic factor for distant-metastases-free survival.
As the value of the CT size of lymph nodes remains almost
unchanged, we assume that this factor is most precise for
defining the probability of distant metastases.
Discussion
Several prognostic factors influencing survival in cervical
cancer patients have been established. Some of these fac-
tors are related to patients' characteristics (age, blood
hemoglobin level), the others being related to tumor
(stage, lymph node involvement, size of tumor) or treat-
ment characteristics (irradiation doses, duration treat-
ment) [19].
Analysis of various factors influencing survival in cervical
cancer patients it usually presumed that cancer in younger
patients is biologically much more aggressive than in
older ones [20,21]. However, data of other authors,
mostly those who analyzed surgical treatment of cervical
cancer, showed that age is not the factor worsening the
prognosis of survival [22]. These differences could occur
due to selecting different treatment options. Surgical treat-
ment is applied mostly to young women with small
tumors. Women of the same age but with big tumors usu-
ally receive radiotherapy. Therefore, the poorer prognosis
in this patients' group could be related not to age, but to
other prognostic factors, e.g. size of the tumor. Our data
confirm this presumption. In our study, age had no
impact on the survival of cervical cancer patients treated
with irradiation.
One of the most significant prognostic factors in cervical
cancer is anemia. We have found that when analyzed
together with other factors, blood Hb level is an inde-
pendent prognostic factor for the overall survival, disease-
Table 2: Univariate analysis of prognostic factors by Cox proportional hazard model: local control and distant metastases-free survival
Factor Local control
RR (95% CI)
p value Distant-metastases-free 
survival
RR (95% CI)
p value
Age 0,98 (95% CI, 0.95–1.01) 0.150 1.00 (95% CI, 0.96–1.03) 0.874
Stage 2.58 (95% CI, 1.14–5.84) 0.023 1.97 (95% CI, 0.78–5.03) 0.154
L/node size by CT 1.64 (95% CI, 1.05–2.56) 0.028 1.87 (95% CI, 1.08–3.21) 0.024
Cervix size by CT 1.29 (95% CI, 0.70–2.40) 0.420 1.05 (95% CI, 0.51–2.17) 0.895
Hb blood level 0.29 (95% CI, 0.14–0.63) 0.002 0.70 (95% CI, 0.29–1.69) 0.427
Dose at point A 0.81 (95% CI, 0.70–1.66) 0.569 1.82 (95% CI, 0.70–4.75) 0.222
Dose at point B 1.64 (95% CI, 0.73–3.67) 0.234 2.56 (95% CI, 0.85-7-69) 0.094
Duration of treatment 1.89 (95% CI, 1.14–3.13) 0.014 2.09 (95% CI, 1.14–3.83) 0.018
Overall survival as a function of radiation treatment duration Figure 7
Overall survival as a function of radiation treatment duration.
  p=0.0094 
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Disease-free survival as a function of radiation treatment  duration Figure 8
Disease-free survival as a function of radiation treatment 
duration.
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free survival and local control; however, it has no prog-
nostic value for distant-metastases-free survival. The
mechanism of relation between anemia and poorer prog-
nosis in cervical cancer patients is unclear. One of the
hypotheses claims that in patients with poor prognosis
anemia is present at the moment of diagnosis. Advocates
of this theory affirm that tumor-related anemia is one of
the signs of tumor aggressiveness, similar to weight loss
and poor performance status [23]. In these cases, correc-
tion of blood Hb level during treatment will have no
impact on the effect of treatment. Another explanation of
the relationship between blood Hb level and prognosis of
the disease could be poor tumor sensitivity to radiother-
apy due to decreased oxygen supply. This hypothesis
allows concluding that blood Hb level correction during
treatment should improve treatment results [20].
There are data showing that the size of cervix evaluated in
CT scans is directly related to the overall survival, disease-
free survival, local control and distant-metastases-free sur-
vival [3,7]. Data of our study have shown, that the CT size
of cervix has no prognostic significance for cervical cancer
patients if only radiotherapy is applied. This discrepancy
should be explained by a relatively low resolving capacity
of CT as regards soft tissue. Therefore it is difficult to dis-
tinguish between specific tumorous infiltration of the par-
ametrium and inflammation and to separate tumor from
normal tissue. The goal of our study was to elucidate the
factors influencing the clinical course without employing
any additional clinical investigations except those rou-
tinely used in everyday practice. Therefore in our study CT
was used for radiotherapy planning without contrast
enhancement, as it defined by the treatment protocol. For
this reasons the resolving capacity and accuracy of some
data could decrease and errors could be bigger.
We have found that enlarged (more than 10 mm) lymph
nodes found by CT before treatment are indicative of a
shorter survival and of a more rapid disease progression of
the cervical cancer patients. It has been proven that the
prognostic value of the size of lymph nodes in CT is of the
same significance for the progression of advanced cervical
cancer as it is in early stages of the disease, when surgery
is applied and the removed lymph nodes are morpholog-
ically evaluated [22]. Therefore we think that when select-
ing the treatment option for advanced cervical cancer
these factors should be taken into account.
According to the literature, clinical stage is one of the
main prognostic factors in cervical cancer patients [24].
Results of our study clearly show that the stage is not an
independent factor which could help predict the clinical
course; it also depends on the other factors which we have
analyzed. Therefore we suppose that other factors such as
size of lymph nodes evaluated by CT should also be taken
into consideration when selecting the treatment option.
Table 4: Multivariate analysis of prognostic factors by Cox proportional hazard model: local control and distant metastases-free 
survival
Factor Local control P Distant-metastases-free 
survival
p
Age 0,98 (95% CI, 0.94–1.01) 0.234 0.99 (95% CI, 0.95–1.03) 0.726
Stage 1.20 (95% CI, 0.47–3.07) 0.770 0.90 (95% CI, 0.30–2.68) 0.856
L/node size by CT 1.67 (95% CI, 1.03–2.70) 0.038 1.79 (95% CI, 0.97–3.31) 0.063
Cervix size by CT 0.87 (95% CI, 0.44–1.72) 0.693 0.82 (95% CI, 0.34–1.98) 0.656
Hb blood level 0.36 (95% CI, 0.16–0.80) 0.013 0.75 (95% CI, 0.28–1.97) 0.555
Dose at point A 0.34 (95% CI, 0.14–0.85) 0.021 0.73 (95% CI, 0.19–2.74) 0.642
Dose at point B 1.71 (95% CI, 0.60–4.88) 0.314 1.68 (95% CI, 0.37–7.51) 0.500
Duration of treatment 1.89 (95% CI, 1.05–3.40) 0.033 1.95 (95% CI, 0.90–4.23) 0.090
Table 3: Multivariate analysis of prognostic factors by Cox proportional hazard model: overall survival and disease-free survival at 3 
years
Factor Overall survival P Disease-free survival P
Age 0.98 (95% CI, 0.97–1.02) 0.565 0.98 (95% CI, 0.95–1.01) 0.201
Stage 2.31 (95% CI, 0.98–5.40) 0.054 1.37 (95% CI, 0.62–3.04) 0.436
L/node size by CT 1.54 (95% CI, 1.04–2.28) 0.030 0.91 (95% CI, 0.51–160) 0.067
Cervix size by CT 1.06 (95% CI, 0.61–1.85) 0.834 0.50 (95% CI, 0.26–0.97) 0.732
Hb blood level 0.35 (95% CI, 0.18–0.67) 0.001 0.41 (95% CI, 0.18–0.91) 0.040
Dose at point A 0.48 (95% CI, 0.22–1.06) 0.070 1.67 (95% CI, 0.67–4.14) 0.028
Dose at point B 1.16 (95% CI, 0.47–2.88) 0.743 1.74 (95% CI, 0.87–3.46) 0.272
Duration of treatment 1.62 (95% CI, 1.01–2.61) 0.045 2.04 (95% CI, 1.23–3.40) 0.006BMC Cancer 2007, 7:234 http://www.biomedcentral.com/1471-2407/7/234
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According to the literature, one of the major prognostic
factors for cervical cancer treated by combined radiother-
apy is irradiation dose at point A, which is applied directly
to the tumor [15,24]. Analysis of the impact of irradiation
dose at point A on survival has shown, that the higher irra-
diation dose is applied at point A, the smaller the proba-
bility of the disease progression, especially of local
recurrence. Univariate and multivariate Cox's analysis has
shown that irradiation dose at point B (tissues surround-
ing cervix uteri) has no prognostic significance. However,
our study is a retrospective one; therefore it was difficult
to evaluate all characteristics of radiotherapy. In this case,
selection of radiotherapy doses was affected by a personal
opinion of the managing physician, by the size of tumor
and other possible factors.
At present, there are a lot of discussions how to reduce
radiotherapy treatment time. According to the literature,
the longer the duration of radiotherapy in cervical cancer,
the shorter is the overall survival, disease-free survival,
and local control [24,25]. Results of our study confirm the
published data that radiotherapy duration is an independ-
ent prognostic factor for overall survival, disease-free sur-
vival, and local control. However, the impact of
radiotherapy on the occurrence of distant metastases is
related to the other prognostic factors we have analyzed.
This effect of the duration of radiotherapy is related to
accelerated clonogenic repopulation, which happens dur-
ing radiotherapy and is especially active in cases of locally
advanced cervical cancers [25]. We have found that the
longer was the duration of treatment, the higher were irra-
diation doses at points A and B. It could be supposed that
increasing the dose was an attempt to compensate for a
gap in radiotherapy. However, our results clearly show
that this is not a sufficient compensation.
At present, chemoradiotherapy is indicated to all patients
with locally advanced (stage IIB-IVA) cervical cancer,
regardless of other factors influencing the survival, which
are taken into account in surgical treatment of early stages.
Data of randomized trials involving 4580 patients
showed that the most beneficial effect of chemoradiother-
apy on survival in comparison with radiotherapy alone
was observed in patients with metastases in pelvic lymph
nodes and large tumor. Stages I and II were found in 68%
of patients involved in clinical trials; most of them had
stage IB tumor with metastases in pelvic lymph nodes and
large tumors found during operations [19]. Data of clini-
cal trials of patients with predominantly advanced cervical
cancer showed that there was no significant survival dif-
ferences in groups of chemoradiotherapy and radiother-
apy alone [17,18]. In our study we analyzed prognostic
factors for uterine cervical cancer treated with radiother-
apy alone and we found some factors significantly influ-
encing the results of treatment. Data of our study show
that the size of lymph nodes in computed tomography is
an independent prognostic factor in cervical cancer
patients undergoing radiotherapy. Although there are no
possibilities to confirm lymph node involvement as can
be done during surgery, it could be assumed that the prog-
nostic significance of this factor in advanced cancer is as
high as in early stages. Therefore we suppose that nodal
status must be taken into account while selecting the treat-
ment strategy for patients with advanced cervical cancer
and patient without lymph nodes involvement on CT
don't need chemoradiotherapy. We propose including
CT-evaluated lymph nodes as additional criteria during
patients' assignment to different arms in clinical trials.
This should be confirmed on prospective randomized tri-
als.
Conclusion
In conclusion, we can say that anemia is a significant and
independent prognostic factor of overall survival, disease-
free survival and local control in cervical cancer patients
treated with irradiation. The size of lymph nodes in CT is
an independent prognostic factor for overall survival and
local control in cervical cancer patients. The size of cervix
uteri evaluated by CT has no prognostic significance in
cervical cancer patients treated with radiotherapy. The
prognostic value of FIGO stage of cervical cancer is influ-
enced by other factors, analyzed in this study and is not an
independent prognostic factor.
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